Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.

Cancers (Basel) · 2022 · PMC8870148 · PMID 35205755

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Furthermore, they found that having a germline mutation was associated with a significantly increased risk of prostate cancer metastases (varying from a nonsignificant relative risk (RR) for ATM mutation (RR: 1.6 (95% CI: 0.8–2.8) to highly significant for individuals with BRCA 2 mutations (RR: 26.7 (95% CI: 18.9–36.4)).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.